Free MTMP Fosamax Femur Fracture TeleSeminar 02/28
FOSAMAX FEMUR FRACTURE: THE EVIDENCE MOUNTS Today’s on-line edition of the Journal of the American Medical Association (JAMA) included publication of a major case control study relating to bisphosphonates (particularly Fosamax) and subtrochanteric femur fractures. The researchers who authored the study concluded that patients on long-term bisphosphonates for osteoporosis therapy had a 274% higher chance of subtrochanteric femur fractures than similar matched patients. (OR 2.74.) The authors concluded “these findings provide strong evidence that prolonged bisphosphonate therapy is associated with an increased risk of subtrochanteric or femoral shaft fracture.” Join us for a free teleseminar on the Fosamax femur fracture litigation including injury and damages profile, scientific evidence discussion, and litigation strategy, hosted by Levin Papantonio partner Tim O’Brien and…
February 23rd, 2011 by admin
